Literature DB >> 16807673

Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis.

Asta Försti1, Qianren Jin, Andrea Altieri, Robert Johansson, Kerstin Wagner, Kerstin Enquist, Ewa Grzybowska, Jolanta Pamula, Wioletta Pekala, Göran Hallmans, Per Lenner, Kari Hemminki.   

Abstract

Angiogenesis is an important step in the development of cancer. Vascular endothelial growth factor is a major regulator of breast cancer angiogenesis, the effects of which are transmitted through the kinase domain receptor (KDR). Up-regulation of KDR by periostin (POSTN) induces angiogenesis. We screened the KDR and the POSTN genes for published single nucleotide polymorphisms (SNPs) and chose two SNPs in each gene for further analyses. We carried out a case-control study consisting of 412 familial and 912 unselected breast cancer cases together with ethnically and geographically selected controls. Genotype, haplotype and genotype combination analyses were carried out to evaluate their effect on susceptibility to and prognosis of breast cancer. A haplotype in the POSTN gene was associated with an increased risk even after correction for multiple comparisons. Nominal associations between the SNPs and prognostic indicators were also observed. Tumors of the KDR 472His allele carriers were less often progesterone receptor negative according to both genotype and haplotype analyses (OR 0.61, 95%CI 0.40-0.92 and OR 0.60, 95%CI 0.40-0.91, respectively). The POSTN -33G allele carriers had more often high grade and estrogen receptor negative tumors (OR 1.75, 95%CI 1.02-3.01 and OR 1.70, 95%CI 1.04-2.78, respectively). The overall and cancer specific survival after 15 years of follow-up was more than 75%, and it did not depend on the genotype. Although a major effect of the SNPs in the KDR and the POSTN genes on breast cancer susceptibility and prognosis was excluded, the effect of the POSTN C-33G SNP on prognosis needs further characterization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16807673     DOI: 10.1007/s10549-006-9265-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  25 in total

1.  Association between genetic variations of vascular endothelial growth factor receptor 2 and glioma in the Chinese Han population.

Authors:  Hongyan Chen; Weimin Wang; Zhao Xingjie; Xiao Song; Weiwei Fan; Zhou Keke; Gong Chen; Yao Zhao; Ying Mao; Daru Lu
Journal:  J Mol Neurosci       Date:  2012-01-25       Impact factor: 3.444

2.  Genetic association of angiogenesis- and hypoxia-related gene polymorphisms with osteonecrosis of the femoral head.

Authors:  Jung Min Hong; Tae Ho Kim; Hyun Ju Kim; Eui Kyun Park; Eun Kyoung Yang; Shin Yoon Kim
Journal:  Exp Mol Med       Date:  2010-05-31       Impact factor: 8.718

3.  The application of gene co-expression network reconstruction based on CNVs and gene expression microarray data in breast cancer.

Authors:  Yan Xu; Huizi Duanmu; Zhiqiang Chang; Shanzhen Zhang; Zhenqi Li; Zihui Li; Yufeng Liu; Kening Li; Fujun Qiu; Xia Li
Journal:  Mol Biol Rep       Date:  2011-05-25       Impact factor: 2.316

4.  Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy.

Authors:  Fei Yang; Ximing Tang; Erick Riquelme; Carmen Behrens; Monique B Nilsson; Uma Giri; Marileila Varella-Garcia; Lauren A Byers; Heather Y Lin; Jing Wang; Maria G Raso; Luc Girard; Kevin Coombes; J Jack Lee; Roy S Herbst; John D Minna; John V Heymach; Ignacio I Wistuba
Journal:  Cancer Res       Date:  2011-07-01       Impact factor: 12.701

5.  Periostin gene polymorphisms, protein levels and risk of incident coronary artery disease.

Authors:  Fangfang Wang; Cuan Yang; Ying Song; Ye Jiang; Zhijian Ding
Journal:  Mol Biol Rep       Date:  2011-05-15       Impact factor: 2.316

6.  Epidermal growth factor receptor pathway polymorphisms and the prognosis of hepatocellular carcinoma.

Authors:  Wenjia Wang; Xiao-Pin Ma; Zhuqing Shi; Pengyin Zhang; Dong-Lin Ding; Hui-Xing Huang; Hexi Ge Saiyin; Tao-Yang Chen; Pei-Xin Lu; Neng-Jin Wang; Hongjie Yu; Jielin Sun; S Lilly Zheng; Long Yu; Jianfeng Xu; De-Ke Jiang
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

7.  Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.

Authors:  Fernando Cruz-Gonzalez; Lucía Cabrillo-Estévez; Gloria López-Valverde; Clara Cieza-Borrella; Emiliano Hernández-Galilea; Rogelio González-Sarmiento
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-13       Impact factor: 3.117

8.  Periostin is up-regulated in high grade and high stage prostate cancer.

Authors:  Verena Tischler; Florian R Fritzsche; Peter J Wild; Carsten Stephan; Hans-Helge Seifert; Marc-Oliver Riener; Thomas Hermanns; Ashkan Mortezavi; Josefine Gerhardt; Peter Schraml; Klaus Jung; Holger Moch; Alex Soltermann; Glen Kristiansen
Journal:  BMC Cancer       Date:  2010-06-09       Impact factor: 4.430

9.  Periostin differentially induces proliferation, contraction and apoptosis of primary Dupuytren's disease and adjacent palmar fascia cells.

Authors:  Linda Vi; Lucy Feng; Rebecca D Zhu; Yan Wu; Latha Satish; Bing Siang Gan; David B O'Gorman
Journal:  Exp Cell Res       Date:  2009-07-18       Impact factor: 3.905

10.  Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration.

Authors:  Amy M Fang; Aaron Y Lee; Mukti Kulkarni; Melissa P Osborn; Milam A Brantley
Journal:  Mol Vis       Date:  2009-12-10       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.